[
    {
        "content": "* Dexcom  inc. Reports record third quarter 2017 financial results",
        "date": "11012017",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Dexcom Inc reports Q3 GAAP loss per share $0.02 "
    },
    {
        "content": "* \u200dTandem Diabetes Care to provide all t:slim x2 insulin pump features approved in 2018 to users at no cost  expands existing dexcom welcome offer for animas customers\u200b",
        "date": "10242017",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-\u200dTandem Diabetes Care to provide all t:slim X2 insulin pump features approved in 2018 to users at no cost "
    },
    {
        "content": "* \u200dJanus Henderson Group PLC reports a 10.2 percent passive stake in  Dexcom Inc as of sept 30 - SEC filing\u200b Source text: (http://bit.ly/2ybb4kH) Further company coverage:",
        "date": "10112017",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-\u200dJanus Henderson reports 10.2 pct passive stake in Dexcom "
    },
    {
        "content": "* \u200dFitbit and DexCom to develop Continuous Glucose Monitoring (CGM) experience for people living with diabetes\u200b",
        "date": "09072017",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Fitbit and Dexcom to develop Continuous Glucose Monitoring Experience for people living with diabetes "
    },
    {
        "content": "* Tandem Diabetes care announces FDA approval and launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration",
        "date": "08282017",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Tandem Diabetes Care announces FDA approval  launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration "
    },
    {
        "content": "* DexCom-\u200d published new study showing type 2 diabetes people on a multiple daily injection insulin therapy benefit from use of continuous glucose monitoring\u200b Source text for Eikon: Further company coverage:",
        "date": "08212017",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-DexCom \u200dpublishes new study on people with type 2 diabetes "
    },
    {
        "content": "* Q2 revenue $170.6 million versus I/B/E/S view $166.3 million",
        "date": "08012017",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Dexcom Q2 revenue $170.6 mln; names new CFO "
    },
    {
        "content": "* Dexcom announces fda approval of g5 mobile app for android devices",
        "date": "06072017",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Dexcom announces FDA approval of G5 mobile app for android devices "
    },
    {
        "content": "* Prices offering of $350 million of 0.75% convertible senior notes",
        "date": "05092017",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Dexcom prices offering of $350 mln of 0.75% convertible senior notes "
    },
    {
        "content": "* Dexcom announces proposed offering of $300 million of convertible senior notes",
        "date": "05082017",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Dexcom announces proposed offering of convertible senior notes "
    },
    {
        "content": "* DexCom appoints Richard Collins to board of directors  Source text for Eikon:  Further company coverage:",
        "date": "03132017",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-DexCom appoints Richard Collins to board of directors "
    },
    {
        "content": "* Dexcom Inc - on February 28  2017  co committed to borrow $75 million in principal amount under its existing $200 million revolving credit facility - SEC filing",
        "date": "03062017",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Dexcom Inc says committed to borrow $75 mln in principal amount under its existing $200 mln revolving credit facility - SEC filing "
    },
    {
        "content": "* Dexcom Inc-  on Feb 14 Jess Roper  chief financial officer notified Dexcom of his decision to resign  effective as of April 1  2017 - sec filing",
        "date": "02212017",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Dexcom says chief financial officer to resign  effective as of April 1 "
    },
    {
        "content": "* Dexcom  inc. Reports fourth quarter and fiscal year 2016 financial results",
        "date": "02282017",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Dexcom Q4 gaap loss per share $0.09 "
    },
    {
        "content": "* Reports 7.25 percent passive stake in Dexcom Inc as of 31 December 2016 - SEC filing  Source text (http://bit.ly/2jwYmFB) Further company coverage:",
        "date": "01202017",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Baillie Gifford & Co reports 7.25% passive stake in Dexcom Inc as of Dec 31  2016 "
    },
    {
        "content": "* Dexcom reports record preliminary  unaudited revenue for the fourth quarter and fiscal year 2016 and provides initial 2017 outlook",
        "date": "01102017",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Dexcom reports record preliminary  unaudited revenue for the Q4 and fiscal year 2016 "
    },
    {
        "content": "* Q3 revenue $148.6 million versus I/B/E/S view $146.3 million",
        "date": "11012016",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-DexCom Q3 GAAP loss per share $0.22 "
    },
    {
        "content": "* Q2 revenue $137.3 million versus I/B/E/S view $132.6 million",
        "date": "08022016",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Dexcom Inc Reports second quarter 2016 financial results "
    },
    {
        "content": "* FDA advisory committee votes in favor of non-adjunctive label for Dexcom G5 Mobile CGM System",
        "date": "07222016",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Dexcom- FDA votes for Dexcom G5 Mobile CGM System non-adjunctive label "
    },
    {
        "content": "* Dexcom Inc says FDA posts briefing documents ahead of advisory committee meeting",
        "date": "07192016",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Dexcom Inc says FDA posts briefing documents ahead of advisory committee meeting "
    },
    {
        "content": "* Says it has sold $7.2 million in equity financing - sec filing",
        "date": "05182016",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Dexcom says sold $7.2 mln in equity financing "
    },
    {
        "content": "* Dexcom Inc files for stock shelf of up to $7.7 million - SEC filing  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "05042016",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Dexcom files for stock shelf of up to $7.7 mln - SEC filing "
    },
    {
        "content": "* Q1 revenue $116.2 million versus i/b/e/s view $110.4 million",
        "date": "04272016",
        "name": "DexCom Inc",
        "news_type": "topStory",
        "symbol": "DXCM",
        "title": "BRIEF-Dexcom reports Q1 loss per share $0.23 "
    }
]